Literature DB >> 26677407

A2A Receptor Antagonists May Potentially Treat Parkinson's Disease.

Ahmed F Abdel-Magid1.   

Abstract

Entities:  

Year:  2014        PMID： 26677407      PMCID： PMC4669984          DOI： 10.1021/ml500312k

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN： 1948-5875            Impact factor:   4.345


× No keyword cloud information.
  4 in total

Review 1.  Adenosine A2A receptor antagonists in Parkinson's disease: progress in clinical trials from the newly approved istradefylline to drugs in early development and those already discontinued.

Authors:  Annalisa Pinna
Journal:  CNS Drugs       Date:  2014-05       Impact factor: 5.749

Review 2.  Past, present and future of A(2A) adenosine receptor antagonists in the therapy of Parkinson's disease.

Authors:  Marie Therese Armentero; Annalisa Pinna; Sergi Ferré; José Luis Lanciego; Christa E Müller; Rafael Franco
Journal:  Pharmacol Ther       Date:  2011-07-23       Impact factor: 12.310

Review 3.  Two new adenosine receptor antagonists for the treatment of Parkinson's disease: istradefylline versus tozadenant.

Authors:  Santiago Perez-Lloret; Marcelo Merello
Journal:  Expert Opin Pharmacother       Date:  2014-03-27       Impact factor: 3.889

Review 4.  Adenosine A2A antagonists in Parkinson's disease: what's next?

Authors:  Patrick Hickey; Mark Stacy
Journal:  Curr Neurol Neurosci Rep       Date:  2012-08       Impact factor: 5.081
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.